White Paper

Natural History Studies: Understanding And Enhancing Their Value In Rare Diseases

Optimizing Rare Disease Outcomes Through eCOA Technology And Training

Successful drug development requires a comprehensive understanding of the underlying disease. To design reliable clinical trials with meaningful, measurable outcome measures, sponsors must apply thorough knowledge of disease presentation, manifestations, and progression, which may be challenging in rare diseases where this information is minimal. Thus, observational studies, encompassing both registry and natural history studies, play important roles in rare disease research. In fact, the value of prospectively designed, protocoldriven natural history studies initiated in the earliest stages of drug development planning cannot be overemphasized.

In this white paper, we discuss the challenges of rare disease development and explore the role of observational studies in informing clinical development, with an emphasis on natural history studies.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader